Author

H. Hammers

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Response assessment of primary kidney tumors in the consolidation cytoreductive and neoadjuvant settings offers a unique opportunity to inform postoperative adaptive treatment strategies. Yet, systematic analyses of nephrectomy specimens post immune checkpoint inhibition (ICI) therapies are lacking. We retrospectively...

P. Kapur, A. Christie, V. Jarmale et al. · Modern Pathology · 0 citations

Open access Sep 2026

1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

Abstract Background The randomized, double-blind, phase 3 LITESPARK-022 study (NCT05239728) showed significant disease-free survival benefit with the addition of belzutifan to adjuvant pembrolizumab in participants with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence following surgery. We presen...

T. Powles, T. Choueiri, J. Karam et al. · The Oncologist · 0 citations

Open access Sep 2026

16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy

Abstract Background ABBV-CLS-484 is a first-in-class oral PTPN2/N1 inhibitor with a dual mechanism of action that both increases the immunogenicity of tumor cells and augments the antitumor T cell response. It has monotherapy efficacy in multiple preclinical tumor models, with comparable activity to anti-PD-1 in many c...

H. Hammers, E. Calvo, B. Carneiro et al. · The Oncologist · 0 citations